Skip to content
HowShorted

Nektar Therapeutics short interest in 2019

In 2019, Nektar Therapeutics's disclosed short interest ran from 11.40% of shares outstanding on 15 Jan 2019 to 16.71% on 31 Dec 2019, a change of +5.31 percentage points. The year's high was 19.73% on 31 Oct 2019 and its low 10.24% on 30 Apr 2019, averaging 14.10% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.89 days on 15 Jul 2019. Full history: Nektar Therapeutics.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Nektar Therapeutics in 2019

2019 in figures

Start of year
11.40% (15 Jan 2019)
End of year
16.71% (31 Dec 2019)
Change
+5.31 pp
High
19.73% (31 Oct 2019)
Low
10.24% (30 Apr 2019)
Average
14.10%
Highest days to cover
19.89 (15 Jul 2019)
SEC filings marked
9

Every report in 2019

Nektar Therapeutics short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201911.40%7.78results (8-K)
31 Jan 201911.51%13.88
15 Feb 201911.13%11.63
28 Feb 201910.71%10.55results (8-K)
15 Mar 201911.35%10.0810-K filed
29 Mar 201910.43%11.36
15 Apr 201910.27%14.84
30 Apr 201910.24%9.76
15 May 201910.41%10.99results (8-K), 10-Q filed
31 May 201912.42%11.99
14 Jun 201912.95%15.10
28 Jun 201913.03%14.79
15 Jul 201913.28%19.89
31 Jul 201913.03%14.12
15 Aug 201915.60%5.25results (8-K), 10-Q filed
30 Aug 201915.85%9.04
13 Sep 201916.31%9.19
30 Sep 201917.63%10.00
15 Oct 201918.98%4.97
31 Oct 201919.73%16.93
15 Nov 201919.60%10.58results (8-K), 10-Q filed
29 Nov 201918.32%9.66
13 Dec 201917.57%14.76
31 Dec 201916.71%18.97

See also: Nektar Therapeutics's full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.